ALK and neuroblastoma: Remarkably, use of BAY 1895344 in this 14 day (3 day on/4 day off) treatment protocol with lorlatinib led to the complete resolution of ALK-driven NB in two independent GEMMs (Rosa26_Alkal2;Th-MYCN and Alk-F1178S;Th-MYCN) with no detectable side effects (Fig. 6).